203 related articles for article (PubMed ID: 30926773)
21. An update and review of antiretroviral therapy.
Piacenti FJ
Pharmacotherapy; 2006 Aug; 26(8):1111-33. PubMed ID: 16863488
[TBL] [Abstract][Full Text] [Related]
22. Nanoparticle-Based ARV Drug Combinations for Synergistic Inhibition of Cell-Free and Cell-Cell HIV Transmission.
Jiang Y; Cao S; Bright DK; Bever AM; Blakney AK; Suydam IT; Woodrow KA
Mol Pharm; 2015 Dec; 12(12):4363-74. PubMed ID: 26529558
[TBL] [Abstract][Full Text] [Related]
23. Antiretroviral resistance in HIV-infected Saudi children failing first-line highly active antiretroviral therapy.
Al Hajjar SH; Frayha H; Althawadi S
Ann Saudi Med; 2012; 32(6):565-9. PubMed ID: 23396017
[TBL] [Abstract][Full Text] [Related]
24. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
Spaulding A; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
[TBL] [Abstract][Full Text] [Related]
25. Prodrug approaches for the development of a long-acting drug delivery systems.
Chien ST; Suydam IT; Woodrow KA
Adv Drug Deliv Rev; 2023 Jul; 198():114860. PubMed ID: 37160248
[TBL] [Abstract][Full Text] [Related]
26. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
[TBL] [Abstract][Full Text] [Related]
27. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.
Palella FJ; Fisher M; Tebas P; Gazzard B; Ruane P; Van Lunzen J; Shamblaw D; Flamm J; Ebrahimi R; Porter D; White K; Hindman J; Elbert E; De-Oertel S; Fralich T
AIDS; 2014 Jan; 28(3):335-44. PubMed ID: 24670520
[TBL] [Abstract][Full Text] [Related]
28. A retrospective evaluation of highly active antiretroviral therapy simplification in patients with end-stage renal disease receiving hemodialysis.
Otto A; Pecora Fulco P
Int J STD AIDS; 2021 Sep; 32(10):963-967. PubMed ID: 33969749
[TBL] [Abstract][Full Text] [Related]
29. Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities.
Ottemann BM; Helmink AJ; Zhang W; Mukadam I; Woldstad C; Hilaire JR; Liu Y; McMillan JM; Edagwa BJ; Mosley RL; Garrison JC; Kevadiya BD; Gendelman HE
Biomaterials; 2018 Dec; 185():174-193. PubMed ID: 30245386
[TBL] [Abstract][Full Text] [Related]
30. Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles.
Zhou T; Su H; Dash P; Lin Z; Dyavar Shetty BL; Kocher T; Szlachetka A; Lamberty B; Fox HS; Poluektova L; Gorantla S; McMillan J; Gautam N; Mosley RL; Alnouti Y; Edagwa B; Gendelman HE
Biomaterials; 2018 Jan; 151():53-65. PubMed ID: 29059541
[TBL] [Abstract][Full Text] [Related]
31. Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy.
Humphreys EH; Chang LW; Harris J
Cochrane Database Syst Rev; 2010 Jun; (6):CD006517. PubMed ID: 20556768
[TBL] [Abstract][Full Text] [Related]
32. Emtricitabine: a novel nucleoside reverse transcriptase inhibitor.
Molina JM; Cox SL
Drugs Today (Barc); 2005 Apr; 41(4):241-52. PubMed ID: 16034488
[TBL] [Abstract][Full Text] [Related]
33. BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial.
Butler K; Inshaw J; Ford D; Bernays S; Scott K; Kenny J; Klein N; Turkova A; Harper L; Nastouli E; Paparini S; Choudhury R; Rhodes T; Babiker A; Gibb D
Health Technol Assess; 2016 Jun; 20(49):1-108. PubMed ID: 27377073
[TBL] [Abstract][Full Text] [Related]
34. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187
[TBL] [Abstract][Full Text] [Related]
35. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Sax PE; Pozniak A; Montes ML; Koenig E; DeJesus E; Stellbrink HJ; Antinori A; Workowski K; Slim J; Reynes J; Garner W; Custodio J; White K; SenGupta D; Cheng A; Quirk E
Lancet; 2017 Nov; 390(10107):2073-2082. PubMed ID: 28867499
[TBL] [Abstract][Full Text] [Related]
36. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
Pinheiro Edos S; Antunes OA; Fortunak JM
Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
[TBL] [Abstract][Full Text] [Related]
37. Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110).
Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
J Acquir Immune Defic Syndr; 2014 Mar; 65(3):318-26. PubMed ID: 24525469
[TBL] [Abstract][Full Text] [Related]
38. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
Margolis DA; Brinson CC; Smith GHR; de Vente J; Hagins DP; Eron JJ; Griffith SK; Clair MHS; Stevens MC; Williams PE; Ford SL; Stancil BS; Bomar MM; Hudson KJ; Smith KY; Spreen WR;
Lancet Infect Dis; 2015 Oct; 15(10):1145-1155. PubMed ID: 26201299
[TBL] [Abstract][Full Text] [Related]
39. An Enhanced Emtricitabine-Loaded Long-Acting Nanoformulation for Prevention or Treatment of HIV Infection.
Mandal S; Belshan M; Holec A; Zhou Y; Destache CJ
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821449
[TBL] [Abstract][Full Text] [Related]
40. Nucleoside and nucleotide reverse transcriptase inhibitors in children.
Giaquinto C; Rampon O; Penazzato M; Fregonese F; De Rossi A; D'Elia R
Clin Drug Investig; 2007; 27(8):509-31. PubMed ID: 17638393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
